Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Adaptive Biotechnologies Corp shares valued at $17,149 were sold by PISKEL KYLE on May 16 ’25. At $8.89 per share, PISKEL KYLE sold 1,929 shares. The insider’s holdings dropped to 277,396 shares worth approximately $2.54 million following the completion of this transaction.
Also, ROBINS HARLAN S sold 68,412 shares, netting a total of over 502,828 in proceeds. Following the sale of shares at $7.35 each, the insider now holds 1,279,524 shares.
Before that, Harlan Robins had added 68,412 shares to its account. In a trade valued at $503,512, the Officer bought Adaptive Biotechnologies Corp shares for $7.36 each.
As published in a research note from Goldman on March 21, 2025, Adaptive Biotechnologies Corp [ADPT] has been rated up from a Neutral to a Buy and the price target has been revised to $9. As of January 05, 2023, Scotiabank has initiated its “Sector outperform” rating for ADPT. Earlier on December 21, 2022, Piper Sandler upgraded its rating. Their new recommendation was “an Overweight” for ADPT stock which previously was a “a Neutral”.
Analyzing ADPT Stock Performance
During the last five days, there has been a drop of approximately -2.24%. Over the course of the year, Adaptive Biotechnologies Corp shares have jumped approximately 52.63%. Shares of the company reached a 52-week high of $10.28 on 05/02/25 and a 52-week low of $5.96 on 01/02/25.
Support And Resistance Levels for Adaptive Biotechnologies Corp (ADPT)
According to the 24-hour chart, there is a support level at 9.00, which, if violated, would cause prices to drop to 8.86. In the upper region, resistance lies at 9.27. The next price resistance is at 9.40. RSI (Relative Strength Index) is 55.80 on the 14-day chart, showing neutral technical sentiment.
